Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Index Rebalance

Apollo Global Management  / Index Rebalance

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.</li>
<li>We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in late-2024/early-2025.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.
We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in late-2024/early-2025.


Quiddity Leaderboard S&P 500 Dec 24: APP, APO, and TPL May Be ADDs, Watch SP600 DELs

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.</li>
<li>We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in the late-2024/early-2025.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
In this insight, we take a look at the upcoming constituent changes in the run up to the December 2024 index rebal event.
We expect two regular changes in December 2024. There are also several live spin-off and M&amp;A events which could trigger intra-review index changes in the late-2024/early-2025.


Quiddity Leaderboard S&P 500 Dec 24 Rebal: APO, CRH, WDAY, TPL

Quiddity Leaderboard S&P 500 Dec 24: Two ADDs (One Biggie), Two DELs, Possible Big Intrareview Moves

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing macroeconomic challenges.</li><li>The company reported a year-over-year revenue stabilization excluding the impact of COVID-19, with a noted 5% revenue increase in non-COVID sectors.</li><li>This performance is underpinned by notable demands in gene therapy services and strategic expansions in the GLP1 (glucagon-like peptide-1) domain, which collectively portend a continuation of mid to high-teens revenue growth for the fiscal year.</li></ul>

Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing macroeconomic challenges.The company reported a year-over-year revenue stabilization excluding the impact of COVID-19, with a noted 5% revenue increase in non-COVID sectors.This performance is underpinned by notable demands in gene therapy services and strategic expansions in the GLP1 (glucagon-like peptide-1) domain, which collectively portend a continuation of mid to high-teens revenue growth for the fiscal year.

Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? - Major Drivers

<ul><li>Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid performance and areas of challenge in their preliminary financial results for the first quarter of fiscal year 2024.</li><li>The company has reaffirmed its full-year guidance, despite the persisting headwinds in various markets which the management team addressed through operational effectiveness and strategic reviews.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid performance and areas of challenge in their preliminary financial results for the first quarter of fiscal year 2024.The company has reaffirmed its full-year guidance, despite the persisting headwinds in various markets which the management team addressed through operational effectiveness and strategic reviews.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Catalent Inc.: Gene Therapy Advancements Indicate A Bright Future Ahead? - Major Drivers

United States

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's oral, injectable, and respiratory delivery technologies address the diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Catalent Inc (CTLT US)

Quiddity Leaderboard S&P 500 Dec 24: APP, APO, and TPL May Be ADDs, Watch SP600 DELs

The S&P500/400/600 Dec24 review will be announced in just over 10 days. There is an intra-review change in SP600 first, and perhaps a few more in...

Travis Lundy

Quiddity Leaderboard S&P 500 Dec 24 Rebal: APO, CRH, WDAY, TPL

The S&P500 rebalance in December is shaping up to be a trade worth $8-13bn a side but there is a possible intra-review change to come as well....

Travis Lundy

Quiddity Leaderboard S&P 500 Dec 24: Two ADDs (One Biggie), Two DELs, Possible Big Intrareview Moves

There are currently two expected ADDs and two expected DELs for the SP500 Dec24 Rebalance. There could be more from spinoffs and mergers. One big...

Travis Lundy

Catalent Inc.: Leveraging Gene Therapy Expertise But Is It Enough? - Major Drivers

Catalent, in its first quarter of fiscal year 2024, has displayed a robust start influenced by solid financial performance, despite the ongoing...

Baptista Research

Catalent Inc.: Gene Therapy Advancements Indicate A Bright Future Ahead? - Major Drivers

Catalent, a global leader in providing development, manufacturing, and delivery technologies for drugs and biologics, has exhibited both solid...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)